Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora a Kinase Inhibitor, in Patients With Advanced Solid Tumors

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-12-0571
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

A Phase I Study of BI 811283, an Aurora B Kinase Inhibitor, in Patients With Advanced Solid Tumors

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2016English

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2013English

Correction: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2015English

A Phase I Pharmacokinetic and Pharmacodynamic Study of PX-12, a Novel Inhibitor of Thioredoxin-1, in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2007English

A Phase I Pharmacokinetic and Pharmacodynamic Study of the Farnesyl Transferase Inhibitor BMS-214662 in Combination With Cisplatin in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2004English

First-In-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients With Advanced Solid Tumors

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients With Advanced Solid Tumors and Liver Metastases

Clinical Cancer Research
Cancer ResearchOncology
2014English

Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor With a Heat Shock Protein-90 Inhibitory Profile, in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2008English

First‐in‐human Phase I Study of E7090, a Novel Selective FGFR Inhibitor, in Patients With Advanced Solid Tumors

Cancer Science
Cancer ResearchMedicineOncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy